Modality
Nanobody
MOA
BCL-2i
Target
MET
Pathway
Notch
MDS
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
~Aug 2018
→ ~Nov 2019
Phase 3
~Feb 2020
→ ~May 2021
NDA/BLA
Aug 2021
→ Oct 2030
NDA/BLACurrent
NCT07973205
2,097 pts·MDS
2021-08→2030-10·Recruiting
2,097 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-134.5y awayPh3 Readout· MDS
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2030-10-13 · 4.5y away
MDS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07973205 | NDA/BLA | MDS | Recruiting | 2097 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |